Gamida Cell Ltd (GMDA) Receives $18.67 Average PT from Brokerages

Shares of Gamida Cell Ltd (NASDAQ:GMDA) have been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $18.67.

A number of research firms have recently weighed in on GMDA. Oppenheimer set a $20.00 price target on Gamida Cell and gave the company a “buy” rating in a report on Tuesday, February 26th. Zacks Investment Research raised Gamida Cell from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Friday, March 1st. Finally, ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a report on Friday, April 5th.

NASDAQ GMDA traded up $0.20 during trading hours on Thursday, reaching $8.65. The company’s stock had a trading volume of 1,617 shares, compared to its average volume of 25,057. Gamida Cell has a 52 week low of $7.99 and a 52 week high of $15.41.

Gamida Cell (NASDAQ:GMDA) last issued its earnings results on Friday, February 8th. The company reported ($14.23) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Gamida Cell will post -1.51 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMDA. Delek Group Ltd. bought a new stake in shares of Gamida Cell during the fourth quarter valued at approximately $298,000. Millennium Management LLC bought a new stake in shares of Gamida Cell during the fourth quarter valued at approximately $210,000. FMR LLC bought a new stake in shares of Gamida Cell during the fourth quarter valued at approximately $1,243,000. Finally, Norges Bank bought a new stake in shares of Gamida Cell during the fourth quarter valued at approximately $88,000. 1.76% of the stock is currently owned by institutional investors.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Featured Story: What is a recession?

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.